AI-generated from publicly available materials.Nabsys is leveraging its Electronic Genome Mapping (EGM) technology to enhance the detection of genomic alterations in hematologic cancers, addressing the limitations of traditional assays.
Hematologic malignancies often involve complex genomic rearrangements such as translocations and deletions that current diagnostic methods struggle to capture comprehensively. Characterization typically requires a combination of techniques like karyotyping and sequencing, each with inherent limitations. At the recent American Society of Human Genetics (ASHG) Annual Meeting, Nabsys presented preliminary findings on its EGM technology, which aims to provide a more holistic view of these alterations.
During a session led by Alka Chaubey, Nabsys showcased how EGM can effectively identify structural and copy number variants, comparing its performance with established cytogenetic methods. The technology, which operates on the OhmX Platform, offers high-resolution insights and is intended to complement existing diagnostic tools rather than replace them. Barrett Bready, CEO of Nabsys, emphasized the need for a comprehensive understanding of genomic changes in blood cancers, highlighting the potential of EGM to fulfill this requirement.
Additionally, Nabsys introduced its Navigator platform, designed for the analysis and visualization of EGM data. This cloud-based tool incorporates user feedback to refine its capabilities, ensuring it meets the practical needs of researchers. The ongoing development of this software, alongside the EGM technology, underscores Nabsys's commitment to advancing research in hematologic malignancies.